Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
U.S. national primate research centers face an uncertain future
The facilities were meant to last 100 years. Four decades shy of that mark, amid flatlined funds and mounting political pressure, their directors are trying to find a path forward.
U.S. national primate research centers face an uncertain future
The facilities were meant to last 100 years. Four decades shy of that mark, amid flatlined funds and mounting political pressure, their directors are trying to find a path forward.
What if nonhuman primate research goes away?
As the U.S. government takes steps to stop using nonhuman primates in research, The Transmitter investigates what that shift could mean for neuroscience.
What if nonhuman primate research goes away?
As the U.S. government takes steps to stop using nonhuman primates in research, The Transmitter investigates what that shift could mean for neuroscience.
The neuroscience questions that need nonhuman primates
The Transmitter asked 17 neuroscientists what questions might remain unanswered if support for nonhuman primate research continues to decline.
The neuroscience questions that need nonhuman primates
The Transmitter asked 17 neuroscientists what questions might remain unanswered if support for nonhuman primate research continues to decline.